MedTrace Logo

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

NCT01726023 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 486

Last updated 2017-09-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.

Conditions

  • Complicated Intra-abdominal Infection

Interventions

DRUG

Ceftazidime-avibactam

Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg

DRUG

metronidazole

Metronidazole 500mg/100ml solution for infusion

DRUG

Meropenem

Meropenem powder for solution for infusion 1000mg

Sponsors & Collaborators

Principal Investigators

  • Paul A Newell, MBBS, MRCP · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • China
  • South Korea
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01726023 on ClinicalTrials.gov